Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout.


Journal

JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160

Informations de publication

Date de publication:
02 08 2022
Historique:
entrez: 2 8 2022
pubmed: 3 8 2022
medline: 5 8 2022
Statut: ppublish

Résumé

Gout is associated with cardiovascular diseases. The temporal association between gout flares and cardiovascular events has not been investigated. To investigate whether there is a transient increase in risk of cardiovascular events after a recent gout flare. A retrospective observational study was conducted using electronic health records from the Clinical Practice Research Datalink in England between January 1, 1997, and December 31, 2020. A multivariable nested case-control study was performed among 62 574 patients with gout, and a self-controlled case series, adjusted for season and age, was performed among 1421 patients with gout flare and cardiovascular event. Gout flares were ascertained using hospitalization, primary care outpatient, and prescription records. The primary outcome was a cardiovascular event, defined as an acute myocardial infarction or stroke. Association with recent prior gout flares was measured using adjusted odds ratios (ORs) with 95% CIs in a nested case-control study and adjusted incidence rate ratios (IRRs) with 95% CIs in a self-controlled case series. Among patients with a new diagnosis of gout (mean age, 76.5 years; 69.3% men, 30.7% women), 10 475 patients with subsequent cardiovascular events were matched with 52 099 patients without cardiovascular events. Patients with cardiovascular events, compared with those who did not have cardiovascular events, had significantly higher odds of gout flare within the prior 0 to 60 days (204/10 475 [2.0%] vs 743/52 099 [1.4%]; adjusted OR, 1.93 [95% CI, 1.57-2.38]) and within the prior 61 to 120 days (170/10 475 [1.6%] vs 628/52 099 [1.2%]; adjusted OR, 1.57 [95% CI, 1.26-1.96]). There was no significant difference in the odds of gout flare within the prior 121 to 180 days (148/10 475 [1.4%] vs 662/52 099 [1.3%]; adjusted OR, 1.06 [95% CI, 0.84-1.34]). In the self-controlled case series (N = 1421), cardiovascular event rates per 1000 person-days were 2.49 (95% CI, 2.16-2.82) within days 0 to 60; 2.16 (95% CI, 1.85-2.47) within days 61 to 120; and 1.70 (95% CI, 1.42-1.98) within days 121 to 180 after a gout flare, compared with cardiovascular event rates of 1.32 (95% CI, 1.23-1.41) per 1000 person-days within the 150 days before or the 181 to 540 days after the gout flare. Compared with 150 days before or the 181 to 540 days after a gout flare, incidence rate differences for cardiovascular events were 1.17 (95% CI, 0.83-1.52) per 1000 person-days, and adjusted IRRs were 1.89 (95% CI, 1.54-2.30) within days 0 to 60; 0.84 (95% CI, 0.52-1.17) per 1000 person-days and 1.64 (95% CI, 1.45-1.86) within days 61 to 120; and 0.38 (95% CI, 0.09-0.67) per 1000 person-days and 1.29 (95% CI, 1.02-1.64) within days 121 to 180 after a gout flare. Among individuals with gout, those who experienced a cardiovascular event, compared with those who did not experience such an event, had significantly higher odds of a recent gout flare in the preceding days. These findings suggest gout flares are associated with a transient increase in cardiovascular events following the flare.

Identifiants

pubmed: 35916846
pii: 2794763
doi: 10.1001/jama.2022.11390
pmc: PMC9346550
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

440-450

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Références

Rheumatology (Oxford). 2011 May;50(5):973-81
pubmed: 21228059
BMJ. 2016 Sep 12;354:i4515
pubmed: 27618829
N Engl J Med. 2002 Jul 4;347(1):5-12
pubmed: 12097534
Epidemiology. 2011 Mar;22(2):228-31
pubmed: 21228697
Arthritis Care Res (Hoboken). 2014 Nov;66(11):1740-8
pubmed: 24664671
Ann Rheum Dis. 2010 Jun;69(6):1162-4
pubmed: 20124358
Emerg Med J. 2011 Oct;28(10):884-6
pubmed: 20826509
Circulation. 2002 Dec 3;106(23):2894-900
pubmed: 12460868
Rheumatology (Oxford). 2013 Jan;52(1):111-7
pubmed: 22787006
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Circulation. 2007 Aug 21;116(8):894-900
pubmed: 17698728
J Korean Med Sci. 2020 May 25;35(20):e133
pubmed: 32449320
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
J Am Coll Cardiol. 2014 Dec 9;64(22):2432-3
pubmed: 25465427
Nat Rev Rheumatol. 2020 Jul;16(7):380-390
pubmed: 32541923
Lancet. 2021 May 15;397(10287):1843-1855
pubmed: 33798500
Circulation. 2004 Jun 1;109(21 Suppl 1):II2-10
pubmed: 15173056
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Arthritis Rheumatol. 2019 Jun;71(6):991-999
pubmed: 30618180
Curr Opin Rheumatol. 2011 Mar;23(2):192-202
pubmed: 21285714
Nature. 2006 Mar 9;440(7081):237-41
pubmed: 16407889
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
Ann Rheum Dis. 2014 Jan;73(1):177-82
pubmed: 23313809
BJGP Open. 2021 Apr 26;5(2):
pubmed: 33234512
N Engl J Med. 2019 Jan 10;380(2):171-176
pubmed: 30625066
BMC Fam Pract. 2010 Jan 05;11:1
pubmed: 20051110
J Clin Epidemiol. 2006 Oct;59(10):1092-101
pubmed: 16980150
Lancet Rheumatol. 2021 Jan;3(1):e58-e70
pubmed: 32904897
Arthritis Rheum. 2006 Aug;54(8):2688-96
pubmed: 16871533
BMC Med Res Methodol. 2005 Jan 25;5(1):5
pubmed: 15670334
Ann Rheum Dis. 2015 Apr;74(4):661-7
pubmed: 24431399
Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1842-8
pubmed: 20595650
Pharmacoepidemiol Drug Saf. 2016 Jul;25(7):820-6
pubmed: 27230083
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175
BMJ. 2013 May 20;346:f2350
pubmed: 23692896

Auteurs

Edoardo Cipolletta (E)

Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom.
Rheumatology Unit, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy.

Laila J Tata (LJ)

Division of Epidemiology and Public Health, University of Nottingham, Nottingham, United Kingdom.

Georgina Nakafero (G)

Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom.

Anthony J Avery (AJ)

Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, United Kingdom.

Mamas A Mamas (MA)

Keele Cardiovascular Research Group, Keele University, Keele, United Kingdom.

Abhishek Abhishek (A)

Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH